Abstract:Abstract Genetic variation of alpha-1 antitrypsin (AAT) is responsible for alpha-1-antitrypsin deficiency (AATD) leading to gain-of-toxic aggregation in the liver and loss-of-function on n eutrophil e lastase (NE) inhibitory activity in the lung contributing to c hronic o bstructive p ulmonary d isease (COPD) during aging. To probe the molecular basis for how biology designs the protein fold to achieve balance between sequence, function and structure contributing to AATD in the population, we measured the intracellular monomer and polymer, secreted monomer and polymer and NE inhibitory activity of 75 alpha-1-antitrypsin (AAT) variants. To address the complex folding dynamics affecting the form and function of the protein fold that is differentially impacted by variants in the population, we applied a G aussian p rocess r egression (GPR) based machine learning approach termed v ariation s patial p rofiling (VSP). By using a sparse collection of extant variants to link genotype to phenotype, VSP maps s patial c o v ariance (SCV) relationships that quantitate the functional value of every residue in the wild-type (WT) AAT sequence with defined uncertainty in the context of its protein fold design. The SCV-based uncertainty allows us to pinpoint critical short- and long-range residue interactions involving 3 regions-the N-terminal (N1), middle (M2) and carboxyl-terminal (C3) of AAT polypeptide sequence that differentially contribute to the balance between function and misfolding of AAT, thus providing an unanticipated platform for precision therapeutic development for liver and lung disease. By understanding mechanistically the complex fold design of the metastable WT AAT fold, we posit that GPR-based SCV provides a foundation for understanding the evolutionary design of the fold from the ensemble of structures found in the population driving biology for precision management of AATD in the individual.

Rare variants in alpha 1 antitrypsin deficiency: a systematic literature review

Rare SERPINA1 variants leading to severe Alpha-1 Antitrypsin Deficiency

Alpha-1 antitrypsin deficiency: A conformational disease associated with lung and liver manifestations

Cleaning up alpha-1 antitrypsin deficiency related liver disease

Ca2+ -regulated secretion of tissue-type plasminogen activator and von Willebrand factor in human endothelial cells.

Case report of a novel alpha1-antitrypsin null variant in Türkiye: Q0RİZE

Future Perspectives in the Diagnosis and Treatment of Liver Disease Associated with Alpha-1 Antitrypsin Deficiency

Advances in Alpha-1-Antitrypsin Deficiency Liver Disease

[Bisalbuminemia. Review and observations on the acquired form in a patient with myeloma].

Antioxidant compounds interfere with the 3.

Liver disease with unknown etiology – have you ruled out alpha-1 antitrypsin deficiency?

Polymer-drug conjugates: current status and future trends.

Update on and future perspectives for the diagnosis of alpha-1 antitrypsin deficiency in Brazil

Quantification of circulating alpha-1-antitrypsin polymers associated with different SERPINA1 genotypes

Variants in autophagy genes MTMR12 and FAM134A are putative modifiers of the hepatic phenotype in α1-antitrypsin deficiency

S4447 Esophageal and Gastric Variceal Hemorrhage Lead to Discovery of Isolated Hepatic Decompensation Secondary to A1AT Deficiency

Profiling Genetic Diversity Reveals the Molecular Basis for Balancing Function with Misfolding in Alpha-1 Antitrypsin

The spectrum of clinical sequelae associated with alpha-1 antitrypsin deficiency

Alpha-1 deficiency in severe asthma patients

Coordination Technology for Collaborative Applications

Immunological and homeostatic pathways of alpha -1 antitrypsin: a new therapeutic potential